NASDAQ · COLL
Healthcare · Drug Manufacturers - Specialty & Generic
$28.50
Up+$0.43 (+1.53%)
Updated Aug 19, 2026, 12:30 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
COLL closed at $28.50 after 21 trading sessions, down 20.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $28.40 | $28.76 | $28.10 | $28.50 | 800.21K |
| Aug 17, 2026 | $28.37 | $29.01 | $27.87 | $28.07 | 865.11K |
| Aug 14, 2026 | $27.59 | $28.52 | $27.135 | $28.23 | 695.33K |
| Aug 13, 2026 | $27.77 | $29.30 | $27.22 | $28.15 | 1.56M |
| Aug 12, 2026 | $26.50 | $26.50 | $25.47 | $25.70 | 1.12M |
| Aug 11, 2026 | $27.20 | $27.44 | $25.90 | $25.98 | 1.29M |
| Aug 10, 2026 | $28.90 | $29.335 | $27.11 | $27.20 | 940.96K |
| Aug 7, 2026 | $29.01 | $29.81 | $28.01 | $29.47 | 978.51K |
| Aug 6, 2026 | $31.675 | $33.03 | $28.90 | $29.11 | 2.13M |
| Aug 5, 2026 | $35.71 | $36.42 | $35.42 | $35.74 | 402.42K |
| Aug 4, 2026 | $35.46 | $36.00 | $35.00 | $35.73 | 438.6K |
| Aug 3, 2026 | $35.43 | $36.45 | $34.68 | $35.58 | 374.25K |
| Jul 31, 2026 | $35.71 | $36.28 | $34.4003 | $35.39 | 288.49K |
| Jul 30, 2026 | $35.72 | $36.40 | $35.175 | $35.98 | 251.22K |
| Jul 29, 2026 | $35.96 | $36.635 | $35.96 | $36.29 | 349.65K |
| Jul 28, 2026 | $36.00 | $36.56 | $35.52 | $35.90 | 225.6K |
| Jul 27, 2026 | $35.44 | $36.03 | $35.26 | $35.52 | 309.71K |
| Jul 24, 2026 | $35.72 | $35.85 | $35.155 | $35.20 | 254.18K |
| Jul 23, 2026 | $34.32 | $35.69 | $34.00 | $35.59 | 253.22K |
| Jul 22, 2026 | $35.89 | $36.51 | $34.59 | $34.72 | 231.34K |
| Jul 21, 2026 | $35.26 | $36.295 | $35.15 | $35.85 | 301.58K |
The latest Smart Investors Daily articles mentioning COLL.
COLL research
Company profile and research snapshot.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | Neutral | — |
| Aug 6, 2026 | Needham | Buy | — |
| Mar 20, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 19, 2026 | Needham | Buy | — |
| Feb 26, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.
SeekingAlpha · Aug 7, 2026
2026-08-07. The following slide deck was published by Collegium Pharmaceutical, Inc.
SeekingAlpha · Aug 6, 2026
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsIan Karp - Head of Investor RelationsVikram...
Benzinga · Aug 6, 2026
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COLL.
